A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors

NCT04911881 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: IBI321

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.